Form 4: Bionano Genomics Officer Acquires Stock Options

Alka Chaubey, Chief Medical Officer of Bionano Genomics, acquired stock options exercisable for 6,966 shares of common stock on March 14, 2025.

Summary

• On March 14, 2025, Alka Chaubey, the Chief Medical Officer of Bionano Genomics, acquired stock options.
• These options grant the right to buy 6,966 shares of Bionano Genomics common stock at an exercise price of $3.47 per share.
• The options vest monthly over 48 months, starting one month after the vesting commencement date, and will be fully vested by the four-year anniversary of that date.
• The expiration date for these options is March 13, 2035.
• Following this transaction, Ms. Chaubey directly owns options for 6,966 shares.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The acquisition of stock options by a key officer aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the Chief Medical Officer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant aligns the interests of the Chief Medical Officer with those of the shareholders, potentially leading to increased focus on long-term value creation.

Key Dates